GlaxoSmithKline (GSK) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BofA/Merrill Lynch Downgrades GlaxoSmithKline (GSK) to Neutral
October 26, 2017 4:42 AM EDTBofA/Merrill Lynch downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Neutral.
Analyst Graham Parry says the valuation is not demanding and sees growing uncertainties likely capping P/E recovery into 2018 stemming from margin pressure and consensus EPS reductions on Advair generics... More
